Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interferes with the binding of beta-catenin to TBL1, which may help stop the growth of tumor cells by blocking the signals passed from one molecule to another inside a cell that tell a cell to grow.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 12 miesięcy do 21 lat (część A) lub do 30 lat (część B)
- •Rozpoznanie potwierdzone histologicznie (badanie tkanki pod mikroskopem) podczas diagnozy lub nawrotu
- •Nowotwory litewate nawracające lub oporyczne, w tym chłoniaki nieziarnicze i guzy typu desmoid
- •Dla części B: raki Ewinga, guzy desmoid, raki kostne, guzy wątroby, guzy Wilmsa lub guzy ze zmianami w szlaku Wnt
- •Widoczne na obrazach guzy, lub w przypadku guzów desmoid - takie, które nie można usunąć operacyjnie i stanowią zagrożenie
- •Dla pacjentów bez wcześniejszego badania genetycznego - wymagane badanie immunohistochemiczne potwierdzające zmiany
Simplified criteria — AI translation
Trial details
- Minimum age
- 12 Months
- Maximum age
- 30 Years
- Last updated (source)
- August 25, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (21)
Children's Hospital of Alabama
Birmingham, United States
Children's Hospital Los Angeles
Los Angeles, United States
Children's Hospital of Orange County
Orange, United States
Lucile Packard Children's Hospital Stanford University
Palo Alto, United States
UCSF Medical Center-Mission Bay
San Francisco, United States
Children's Hospital Colorado
Aurora, United States
Children's National Medical Center
Washington D.C., United States
Children's Healthcare of Atlanta - Arthur M Blank Hospital
Atlanta, United States
Lurie Children's Hospital-Chicago
Chicago, United States
Riley Hospital for Children
Indianapolis, United States
Dana-Farber Cancer Institute
Boston, United States
C S Mott Children's Hospital
Ann Arbor, United States
University of Minnesota/Masonic Cancer Center
Minneapolis, United States
Washington University School of Medicine
St Louis, United States
NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
New York, United States
Cincinnati Children's Hospital Medical Center
Cincinnati, United States
Children's Hospital of Philadelphia
Philadelphia, United States
Children's Hospital of Pittsburgh of UPMC
Pittsburgh, United States
Saint Jude Children's Research Hospital
Memphis, United States
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
Houston, United States
Seattle Children's Hospital
Seattle, United States
Trial contact
Site Public Contact
Girish Dhall
PRINCIPAL_INVESTIGATOR
Site Public Contact
Fariba Navid
PRINCIPAL_INVESTIGATOR
Site Public Contact
Elyssa M. Rubin
PRINCIPAL_INVESTIGATOR
Site Public Contact
Kieuhoa T. Vo
PRINCIPAL_INVESTIGATOR
Site Public Contact
Margaret E. Macy
PRINCIPAL_INVESTIGATOR
Site Public Contact
AeRang Kim
PRINCIPAL_INVESTIGATOR
Site Public Contact
William T. Cash
PRINCIPAL_INVESTIGATOR
Site Public Contact
Elizabeth A. Sokol
PRINCIPAL_INVESTIGATOR
Site Public Contact
Brian D. Weiss
PRINCIPAL_INVESTIGATOR
Site Public Contact
Steven G. DuBois
PRINCIPAL_INVESTIGATOR
Site Public Contact
Rajen Mody
PRINCIPAL_INVESTIGATOR
Site Public Contact
Robin L. Williams
PRINCIPAL_INVESTIGATOR
Site Public Contact
Shalini Shenoy
PRINCIPAL_INVESTIGATOR
Site Public Contact
Nobuko Hijiya
PRINCIPAL_INVESTIGATOR
Site Public Contact
Joseph G. Pressey
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jacquelyn Crane
PRINCIPAL_INVESTIGATOR
Site Public Contact
Andrew Bukowinski
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jessica Gartrell
PRINCIPAL_INVESTIGATOR
Site Public Contact
Jennifer H. Foster
PRINCIPAL_INVESTIGATOR
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 8/26/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.